Combination of Docetaxel + Estramustine + Hydrocortisone Versus Docetaxel + Prednisone in Patients With Advanced Prostate Cancer Who Have Relapse in Biochemistry Whilst Androgenic Blockage
Phase of Trial: Phase III
Latest Information Update: 01 Jun 2011
At a glance
- Drugs Docetaxel; Estramustine; Hydrocortisone; Prednisone
- Indications Prostate cancer
- Focus Therapeutic Use
- Acronyms PROSTATA
- Sponsors Sanofi
- 10 Jun 2017 Biomarkers information updated
- 29 Nov 2010 Planned end date changed from 1 Jan 2010 to 1 Jul 2009 as reported by ClinicalTrials.gov.
- 29 Nov 2010 Actual patient number is 54 as reported by ClinicalTrials.gov.